Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death
Open accessThe DOI matches its Crossref record; 131 of the 135 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Named as the guardian of the genome, p53 is a tumor suppressor that regulates cell function, often through many different mechanisms such as DNA repair, apoptosis, cell cycle arrest, senescence, metabolism, and autophagy. One of the genes that p53 activates is MDM2, which forms a negative feedback loop since MDM2 induces the degradation of p53. When p53 activity is inhibited, damaged cells do not undergo cell cycle arrest or apoptosis. As 50% of human cancers inactivate p53 by mutation, current research focuses on reactivating p53 by developing drugs that target the p53-MDM2 interaction, which includes the binding of MDM2 and phosphorylation of p53. The objective of this article is to provide a short list and description of p53-MDM2 antagonists that may be excellent candidates for inducing cancer cell death. Relevant articles were searched for and identified using online databases such as PubMed and ScienceDirect. Increasing p53 levels, by targeting the p53-MDM2 interaction, can help p53 play its role as a tumor suppressor and induce cancer cell death. Researchers have identified different compounds that can act as inhibitors, either by directly binding to MDM2 or by modifying p53 with phosphorylation. The results associated with the drugs demonstrate the importance of targeting such interactions to inhibit cancer cell growth, which indicates that the use of the compounds may improve cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although a limitation is the differing subcutaneous tumor microenvironment, there is strong evidence that the cytotoxicity of MDM2 inhibitors is largely tumor cell autonomous (39, 40).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016) · Journal of Nutritional Science · doi:10.1017/jns.2016.41 · Cited by 5,298
Chemistry and Biological Activities of Flavonoids: An Overview
Kumar, S., & Pandey, A. K. (2013) · The Scientific World Journal · doi:10.1155/2013/162750 · Cited by 4,980
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797
Concepts in sumoylation: a decade on
Geiss-Friedlander, R., & Melchior, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2293 · Cited by 1,785
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
DNA Damage Sensing by the ATM and ATR Kinases
Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222
Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 1,074
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959
p53 ubiquitination: Mdm2 and beyond
Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Acetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838
Regulation of p53 activity through lysine methylation
Chuikov, S., Kurash, J. K., Wilson, J. R., Xiao, B., Justin, N., Ivanov, G. S., McKinney, K., Tempst, P., Prives, C., Gamblin, S. J., et al. (2004) · Nature · doi:10.1038/nature03117 · Cited by 816
Chk2/hCds1 functions as a DNA damage checkpoint in G1by stabilizing p53
Chehab, N. H., Malikzay, A., Appel, M., & Halazonetis, T. D. (2000) · Genes & Development · doi:10.1101/gad.14.3.278 · Cited by 805
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
CYCLINS AND CELL CYCLE CHECKPOINTS
Johnson, D. G., & Walker, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.295 · Cited by 719
Foster, K. A., Oster, C. G., Mayer, M. M., Avery, M. L., & Audus, K. L. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4172 · Cited by 713
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin
Takagi, M., Absalon, M. J., McLure, K. G., & Kastan, M. B. (2005) · Cell · doi:10.1016/j.cell.2005.07.034 · Cited by 663
SUMO-1 modification activates the transcriptional response of p53
Rodriguez, M. S., Desterro, J. M. P., Lain, S., Midgley, C. A., Lane, D. P., & Hay, R. T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.22.6455 · Cited by 639
Repression of p53 activity by Smyd2-mediated methylation
Huang, J., Perez-Burgos, L., Placek, B. J., Sengupta, R., Richter, M., Dorsey, J. A., Kubicek, S., Opravil, S., Jenuwein, T., & Berger, S. L. (2006) · Nature · doi:10.1038/nature05287 · Cited by 624
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
p53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity
Xirodimas, D. P., Saville, M. K., Bourdon, J.-C., Hay, R. T., & Lane, D. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.016 · Cited by 570
Characterization of NEDD8, a Developmentally Down-regulated Ubiquitin-like Protein
Kamitani, T., Kito, K., Nguyen, H. P., & Yeh, E. T. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28557 · Cited by 535
Acetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
Iwakuma, T., & Lozano, G. (2003) · PubMed · Cited by 503
Modulation of p53 Function by SET8-Mediated Methylation at Lysine 382
Shi, X., Kachirskaia, I., Yamaguchi, H., West, L. E., Wen, H., Wang, E. W., Dutta, S., Appella, E., & Gozani, O. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.07.012 · Cited by 462
Arginine methylation regulates the p53 response
Jansson, M., Durant, S. T., Cho, E.-C., Sheahan, S., Edelmann, M., Kessler, B., & La Thangue, N. B. (2008) · Nature Cell Biology · doi:10.1038/ncb1802 · Cited by 462
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 461
Mechanisms of transcriptional regulation by p53
Sullivan, K. D., Galbraith, M. D., Andrysik, Z., & Espinosa, J. M. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.174 · Cited by 446
Structure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 434
Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response
Cazzalini, O., Scovassi, A. I., Savio, M., Stivala, L. A., & Prosperi, E. (2010) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2010.01.009 · Cited by 433
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
Unger, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1805 · Cited by 367
The Tumor Suppressor p53: From Structures to Drug Discovery
Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 357
Function and regulation of protein neddylation
Rabut, G., & Peter, M. (2008) · EMBO reports · doi:10.1038/embor.2008.183 · Cited by 350
Various modes of cell death induced by DNA damage
Surova, O., & Zhivotovsky, B. (2013) · Oncogene · doi:10.1038/onc.2012.556 · Cited by 334
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328
White, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026120 · Cited by 320
Design, Synthesis, and Evaluation of Novel Boronic-Chalcone Derivatives as Antitumor Agents
Kumar, S. K., Hager, E., Pettit, C., Gurulingappa, H., Davidson, N. E., & Khan, S. R. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030213+ · Cited by 303
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
Venot, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4668 · Cited by 292
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290
Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2001) · Biochemistry · doi:10.1021/bi000930v · Cited by 275
DNA damage kinase signaling: checkpoint and repair at 30 years
Lanz, M. C., Dibitetto, D., & Smolka, M. B. (2019) · The EMBO Journal · doi:10.15252/embj.2019101801 · Cited by 260
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
Crystal structure of human CDK4 in complex with a D-type cyclin
Day, P. J., Cleasby, A., Tickle, I. J., O'Reilly, M., Coyle, J. E., Holding, F. P., McMenamin, R. L., Yon, J., Chopra, R., Lengauer, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809645106 · Cited by 232
Nasopharyngeal carcinoma: A review
Petersson, F. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.021 · Cited by 222
FBXO11 Promotes the Neddylation of p53 and Inhibits Its Transcriptional Activity
Abida, W. M., Nikolaev, A., Zhao, W., Zhang, W., & Gu, W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609001200 · Cited by 203
Ou, Y.-H., Chung, P.-H., Sun, T.-P., & Shieh, S.-Y. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0689 · Cited by 198
Structure, Function, and Aggregation of the Zinc-Free Form of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2003) · Biochemistry · doi:10.1021/bi026635n · Cited by 191
Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas
Zhang, L., Chen, L. H., Wan, H., Yang, R., Wang, Z., Feng, J., Yang, S., Jones, S., Wang, S., Zhou, W., et al. (2014) · Nature Genetics · doi:10.1038/ng.2995 · Cited by 187
Autophagy, Metabolism, and Cancer
Guo, J. Y., & White, E. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030981 · Cited by 180
Recent progress in sodium channel modulators for pain
Bagal, S. K., Chapman, M. L., Marron, B. E., Prime, R., Storer, R. I., & Swain, N. A. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.038 · Cited by 177
Isolation and Structure Elucidation of Chlorofusin, a Novel p53-MDM2 Antagonist from a Fusarium sp.
Duncan, S. J., Grüschow, S., Williams, D. H., McNicholas, C., Purewal, R., Hajek, M., Gerlitz, M., Martin, S., Wrigley, S. K., & Moore, M. (2001) · Journal of the American Chemical Society · doi:10.1021/ja002940p · Cited by 172
Phosphorylation of murine p53 at Ser-18 regulates the p53 responses to DNA damage
Chao, C., Saito, S., Anderson, C. W., Appella, E., & Xu, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220252297 · Cited by 166
Recent Advances in the Therapeutic Perspectives of Nutlin-3
Secchiero, P., Bosco, R., Celeghini, C., & Zauli, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222586 · Cited by 158
Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152
New Insights into the Link Between DNA Damage and Apoptosis
De Zio, D., Cianfanelli, V., & Cecconi, F. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4938 · Cited by 152
Lindstroöm, M. S., Jin, A., Deisenroth, C., White Wolf, G., & Zhang, Y. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-06 · Cited by 152
Persistent use of “false” cell lines
Lacroix, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23233 · Cited by 151
Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Shen, H., & G. Maki, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 147
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
Barbieri, E., Mehta, P. S., Chen, Z., Zhang, L., Slack, A., Berg, S. L., & Shohet, J. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0305 · Cited by 147
Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Jandial, D., Blair, C., Zhang, S., Krill, L. S., Zhang, Y., & Zi, X. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140122160515 · Cited by 137
The missing Zinc: p53 misfolding and cancer
Loh, S. N. (2010) · Metallomics · doi:10.1039/c003915b · Cited by 133
Dornan, D., Shimizu, H., Burch, L. R., Smith, A. J., & Hupp, T. R. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8846-8861.2003 · Cited by 130
Chen, J., & Kastan, M. B. (2010) · Genes & Development · doi:10.1101/gad.1968910 · Cited by 127
Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2
Maki, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16531 · Cited by 126
Laptenko, O., Shiff, I., Freed-Pastor, W., Zupnick, A., Mattia, M., Freulich, E., Shamir, I., Kadouri, N., Kahan, T., Manfredi, J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.015 · Cited by 119
DNA-dependent Acetylation of p53 by the Transcription Coactivator p300
Dornan, D., Shimizu, H., Perkins, N. D., & Hupp, T. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211460200 · Cited by 116
A Genetic Approach to Mapping the p53 Binding Site in the MDM2 Protein
Freedman, D. A., Epstein, C. B., Roth, J. C., & Levine, A. J. (1997) · Molecular Medicine · doi:10.1007/bf03401678 · Cited by 113
Recommendations on reporting requirements for flavonoids in research
Balentine, D. A., Dwyer, J. T., Erdman, J. W., Ferruzzi, M. G., Gaine, P. C., Harnly, J. M., & Kwik-Uribe, C. L. (2015) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.071274 · Cited by 110
Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
Kang, Y., He, W., Ren, C., Qiao, J., Guo, Q., Hu, J., Xu, H., Jiang, X., & Wang, L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00340-2 · Cited by 110
Qin, J.-J., Li, X., Hunt, C., Wang, W., Wang, H., & Zhang, R. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.07.002 · Cited by 108
Transcription factors that interact with p53 and Mdm2
Inoue, K., Fry, E. A., & Frazier, D. P. (2016) · International Journal of Cancer · doi:10.1002/ijc.29663 · Cited by 103
Khurana, A., & Shafer, D. A. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s172315 · Cited by 102
Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway
Lü, Y., Sun, Y., Zhu, J., Yu, L., Jiang, X., Zhang, J., Dong, X., Ma, B., & Zhang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0031-6 · Cited by 101
Natan, E., Baloğlu, Ç., Pagel, K., Freund, S. M. V., Morgner, N., Robinson, C. V., Fersht, A. R., & Joerger, A. C. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.047 · Cited by 100
Indole-3-carbinol: a plant hormone combatting cancer
Katz, E., Nisani, S., & Chamovitz, D. (2018) · F1000Research · doi:10.12688/f1000research.14127.1 · Cited by 96
Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation
Damia, G., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., Dincalci, M., & Broggini, M. (2001) · Neoplasia · doi:10.1038/sj.neo.7900122 · Cited by 92
Tsukamoto, S., Yoshida, T., Hosono, H., Ohta, T., & Yokosawa, H. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.052 · Cited by 89
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
Cao, C., Shinohara, E. T., Subhawong, T. K., Geng, L., Woon Kim, K., Albert, J. M., Hallahan, D. E., & Lu, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0356 · Cited by 85
p76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53
Perry, M. E., Mendrysa, S. M., Saucedo, L. J., Tannous, P., & Holubar, M. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5733 · Cited by 83
Brew, C. T., Aronchik, I., Hsu, J. C., Sheen, J.-H., Dickson, R. B., Bjeldanes, L. F., & Firestone, G. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21445 · Cited by 83
Effect of Zn2+ on DNA Recognition and Stability of the p53 DNA-Binding Domain
Duan, J., & Nilsson, L. (2006) · Biochemistry · doi:10.1021/bi0603165 · Cited by 80
Shellfish Toxins Targeting Voltage-Gated Sodium Channels
Zhang, F., Xu, X., Li, T., & Liu, Z. (2013) · Marine Drugs · doi:10.3390/md11124698 · Cited by 80
p53 Oligomerization Is Essential for Its C-terminal Lysine Acetylation
Itahana, Y., Ke, H., & Zhang, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805696200 · Cited by 74
Gartel, A. L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0163 · Cited by 74
Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2
Vogel, S. M., Bauer, M. R., Joerger, A. C., Wilcken, R., Brandt, T., Veprintsev, D. B., Rutherford, T. J., Fersht, A. R., & Boeckler, F. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215060109 · Cited by 74
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
Skalniak, L., Kocik, J., Polak, J., Skalniak, A., Rak, M., Wolnicka-Glubisz, A., & Holak, T. (2018) · Cancers · doi:10.3390/cancers10110396 · Cited by 73
Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction
Malloy, K. L., Choi, H., Fiorilla, C., Valeriote, F. A., Matainaho, T., & Gerwick, W. H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.10.054 · Cited by 71
Luo, H., Yount, C., Lang, H., Yang, A., Riemer, E. C., Lyons, K., Vanek, K. N., Silvestri, G. A., Schulte, B. A., & Wang, G. Y. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.017 · Cited by 66
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
Sahin, I., Zhang, S., Navaraj, A., Zhou, L., Dizon, D., Safran, H., & El-Deiry, W. S. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0292-1 · Cited by 66
Chen, C., Hsu, Y., Chen, Y., Hung, J., Huang, M., & Kuo, P. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.028 · Cited by 66
Kachnic, L. A., Wu, B., Wunsch, H., Mekeel, K. L., DeFrank, J. S., Tang, W., & Powell, S. N. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13111 · Cited by 65
Hsu, Y., Uen, Y., Chen, Y., Liang, H., & Kuo, P. (2009) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf901053x · Cited by 65
p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53
Carter, S. A., & Vousden, K. H. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6422 · Cited by 60
p53 binding to the p21 promoter is dependent on the nature of DNA damage
Bodzak, E., Blough, M. D., Lee, P. W. K., & Hill, R. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6440 · Cited by 59
MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms053 · Cited by 58
Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction
Beloglazkina, A., Zyk, N., Majouga, A., & Beloglazkina, E. (2020) · Molecules · doi:10.3390/molecules25051211 · Cited by 58
Recent Advances in Cancer Therapeutics
Chessum, N. E. A., Jones, K., Pasqua, E., & Tucker, M. (2015) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2014.11.002 · Cited by 53
Choi, M., Shi, J., Zhu, Y., Yang, R., & Cho, K. (2017) · Nature Communications · doi:10.1038/s41467-017-02160-5 · Cited by 53
ATM, radiation, and the risk of second primary breast cancer
Bernstein, J. L., WECARE Study Collaborative Group, & Concannon, P. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1344363 · Cited by 50
Rigatti, M. J., Verma, R., Belinsky, G. S., Rosenberg, D. W., & Giardina, C. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.20795 · Cited by 45
Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity
VOON, Y.-L., Ahmad, M., Wong, P., Husaini, R., Ng, W., Leong, C., Lane, D. P., & Khoo, A. S. B. (2015) · Oncology Reports · doi:10.3892/or.2015.4177 · Cited by 44
Tichý, A., Vávrová, J., Pejchal, J., & Řezáčová, M. (2010) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2016.57 · Cited by 43
Peirce, S. K., Findley, H. W., Prince, C. Z., Dasgupta, A., Cooper, T. M., & Durden, D. L. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1486-7 · Cited by 42
Clark, R. C., Lee, S. Y., Searcey, M., & Boger, D. L. (2009) · Natural Product Reports · doi:10.1039/b821676b · Cited by 40
Bessette, D. C., Tilch, E., Seidens, T., Quinn, M. C. J., Wiegmans, A. P., Shi, W., Cocciardi, S., Reed, A. E. M., Saunus, J. M., Simpson, P. T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125232 · Cited by 39
Patil, S. P., Pacitti, M. F., Gilroy, K. S., Ruggiero, J. C., Griffin, J. D., Butera, J. J., Notarfrancesco, J. M., Tran, S., & Stoddart, J. W. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9811-6 · Cited by 38
Stereochemical studies of hexylitaconic acid, an inhibitor of p53–HDM2 interaction
Nakahashi, A., Miura, N., Monde, K., & Tsukamoto, S. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.057 · Cited by 36
The relevance of protein-protein interactions for p53 function: the CPE contribution
Fernández-Fernández, M. R., & Sot, B. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq074 · Cited by 35
The roles of MDM2 and MDMX phosphorylation in stress signaling to p53
Chen, J. (2012) · Genes & Cancer · doi:10.1177/1947601912454733 · Cited by 33
Mdm2 and MdmX: Partners in p53 Destruction
Manfredi, J. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0145 · Cited by 28
Commentary on “Participation of p53 Protein in the Cellular Response to DNA Damage”
Kastan, M. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1560 · Cited by 25
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
Xu, C., Liu, H., Pirozzi, C. J., Chen, L. H., Greer, P. K., Diplas, B. H., Zhang, L., Waitkus, M. S., He, Y., & Yan, H. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01270-y · Cited by 24
Kong, X., Gao, H.-X., & Stanbridge, E. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103681200 · Cited by 22
A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2
ElSawy, K. M., Sim, A. Y. L., Lane, D. P., Verma, C. S., & Caves, L. S. D. (2015) · Cell Cycle · doi:10.4161/15384101.2014.989043 · Cited by 14
Fluspirilene in the treatment of non-hospitalized schizophrenic patients
Soni, S. D. (1977) · Current Medical Research and Opinion · doi:10.1185/03007997709115285 · Cited by 8
Zhou, X., Niu, X., Liu, P., Ou, D., Zhu, Y., & Wang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762663 · Cited by 8
Cited by
Qin, R., You, F.-M., Zhao, Q., Xie, X., Peng, C., Zhan, G., & Han, B. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01350-z · Cited by 139
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Huang, Y., Che, X., Wang, P. W., & Qu, X. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.05.001 · Cited by 94
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
Wallis, B., Bowman, K. E. R., Lu, P., & Lim, C. S. (2023) · Biomolecules · doi:10.3390/biom13010159 · Cited by 63
Vicente, A. T. S., & Salvador, J. A. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911068 · Cited by 56
De novo molecular design with deep molecular generative models for PPI inhibitors
Wang, J., Chu, Y., Mao, J., Jeon, H.-N., Jin, H., Zeb, A., Jang, Y., Cho, K.-H., Song, T., & No, K. T. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac285 · Cited by 53
Metadata
- Authors
- Koo, N., Sharma, A. K., & Narayan, S.
- Affiliations
- University of Florida (US)
- Penn State Cancer Institute (US)
- Corresponding author
- Narayan, Satya
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-30
- Volume
- 23
- Issue
- 9
- Pages
- 5005
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9103871
- OpenAlex
- W4225255854
- Cited by
- 153
- References
- 135
- Citations by year
- 2026: 32 · 2025: 46 · 2024: 43 · 2023: 19 · 2022: 13
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Department of Anatomy and Cell Biology, University of Florida
- Department of Pharmacology, Penn State University College of Medicine
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, MDM2, p53-MDM2 interaction, p53 reactivation, MDM2 inhibitors, p53 phosphorylation, tumor suppressor, cancer cell death, apoptosis, cell cycle arrest, cancer therapeutics
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Tumor Suppressor Protein p53, Cell Death, Apoptosis, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.